RBC Capital Sees Tough Road Ahead Following Orexigen Therapeutics' (OREX) Takeda Partnership Termination; Cuts PT to $0.60

Leerink Lowers Leerink (OREX) PT to $1 on Move to Acquire Contrave Rights from Takeda

Leerink Partners analyst, Paul Matteis, noted that Orexigen Therapeutics (NASDAQ: OREX) acquired the Contrave rights from Takeda and lowered his price target to $1 (from $2) on shares as a result. The firm maintained its Market Perform rating.

Yesterday morning OREX announced that it has entered into a deal with Takeda where it will acquire US commercial rights to Contrave; concurrently, OREX also... More

Piper Jaffray Downgrades Orexigen Therapeutics (OREX) to Neutral

Piper Jaffray downgraded Orexigen Therapeutics (NASDAQ: OREX) from Overweight to Neutral with a price target of $2.00 (from $5.00).

Analyst Charles Duncan commented, "Yesterday Orexigen announced it plans to terminate its commercial partnership with Takeda for Contrave in the US market. We believe this... More

JMP Securities Downgrades Orexigen Therapeutics (OREX) to Market Perform

JMP Securities downgraded Orexigen Therapeutics (NASDAQ: OREX) from Market Outperform to Market Perform and removed its price target (prior $2.00).

For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on Orexigen Therapeutics click here.

Shares of Orexigen Therapeutics closed at $0.64 yesterday.

Orexigen Therapeutics (OREX) Files $150M Mixed Shelf

Orexigen Therapeutics (NASDAQ: OREX) filed a registration with the U.S. SEC to sell up to $150 million worth of mixed securities.

Pre-Open Stock Movers 03/15: (CPXX) (SZYM) (ESI) Higher; (VRX) (LINE) (DDD) Lower (more...)

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) 409.5% HIGHER; announced positive results from the Phase 3 trial of VYXEOS (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. The trial met its primary endpoint demonstrating a statistically significant improvement in overall survival.

Solazyme, Inc. (Nasdaq: SZYM) 37.9% HIGHER; has signed a... More

Orexigen Therapeutics (OREX) Enters Mysimba Commercialization Agreement with Valeant (VRX)

Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. The distribution agreement between Valeant Holdings Ireland and Orexigen's wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., includes 12 countries where Mysimba has been approved for marketing in the European Union (EU): Greece, Slovenia, Slovakia, Czech Republic, Hungary, Croatia, Lithuania, Estonia, Poland, Latvia, Bulgaria, and Romania. The agreement also extends to several non-EU countries where Valeant will apply for marketing authorization: Serbia, Bosnia and Herzegovina, Albania, Macedonia, Montenegro,... More

Orexigen (OREX), Takeda to Terminate CONTRAVE Amended, Restated Collaboration Agreement

Orexigen Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, announced they have agreed to terminate the Amended and Restated Collaboration Agreement for CONTRAVE (naltrexone HCl / bupropion HCl), the market leading national branded prescription treatment option for certain overweight and obese adults for... More